Faculty of 1000 evaluation for Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Neyssa Marina
  • March 2012, Faculty of 1000, Ltd.
  • DOI: 10.3410/f.13996967.15453074

The authors haven't yet claimed this publication.

open access logoRead Publication

http://dx.doi.org/10.3410/f.13996967.15453074

In partnership with: